Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab. Participants will receive either: * Rina-S monotherapy (by itself), * Rina-S plus bevacizumab, * investigator's choice chemotherapy (by itself) (standard of care), or * investigator's choice chemotherapy plus bevacizumab (standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak jajnika typu wysoko złośliwego (serous lub endometrioid)
- •Rak powrócił lub pogorszył się po pierwszym leczeniu chemią (karboplatyna + paklitaksel)
- •Rak wrócił co najmniej 6 miesięcy po ostatniej dawce chemii platynowej
- •Pacjentki z mutacją BRCA musiały wcześniej przyjmować inhibitory PARP
- •Widoczne zmiany nowotworowe na badaniach obrazowych
- •Próbka tkanki nowotworu dostarczona do badania
- •Ogólny stan zdrowia pacjentki pozwala na leczenie (status ECOG 0-1)
✗ Disqualifies
- •Rak jajnika typu jasnokomórkowy, śluzowy lub mięsakowaty
- •Wcześniejsze leczenie innymi lekami hamującymi tworzenie naczyń (poza bevacizumabem)
- •Wcześniejsza terapia lekami ADC zawierającymi inhibitor topoisomerazy-1
- •Wcześniejsza terapia lekami ADC ukierunkowanymi na receptor folatowy alfa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Danbury Hospital
Danbury, United States
ProHealth Care Inc
Waukesha, United States
Trial contact
Genmab Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.